Serum cytokine and chemokine profiles in patients with myasthenia gravis

Clinical and Experimental Immunology

Volumn 176, Issue 2, 2014, Pages 232-237

  Uzawa, A ^a   Kawaguchi, N ^a,b   Himuro, K ^a   Kanai, T ^a   Kuwabara, S ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Neurology Chiba Clinic   (Japan)

Author keywords

Interleukin 15; Interleukin 4; Myasthenia gravis; Thymoma; Vascular endothelial growth factor (VEGF)

Indexed keywords

EOTAXIN; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; JAPANESE; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THYMOMA; VERY ELDERLY;

INTERLEUKIN-15; INTERLEUKIN-4; MYASTHENIA GRAVIS; THYMOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF);

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CHEMOKINES; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-15; INTERLEUKIN-4; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897948572     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12272     Document Type: Article

References (21)

1. Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330:1797-1810.
2. Nagvekar N, Moody AM, Moss P etal. A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4-producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J Clin Invest 1998; 101:2268-2277.
3. Tüzün E, Scott BG, Goluszko E, Higgs S, Christadoss P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol 2003; 171:3847-3854.
4. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338:436-445.
5. Jutel M, Akdis CA. T-cell subset regulation in atopy. Curr Allergy Asthma Rep 2011; 11:139-145.
6. Yang H, Zhang Y, Wu M etal. Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile. Inflamm Res 2010; 59:197-205.
7. Roche JC, Capablo JL, Larrad L etal. Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve 2011; 44:278-280.
8. Zheng S, Dou C, Xin N etal. Expression of interleukin-22 in myasthenia gravis. Scand J Immunol 2013; 78:98-107.
9. Jaretzki A 3rd, Barohn RJ, Ernstoff RM etal. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000; 55:16-23.
10. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999; 52:1487-1489.
11. Uzawa A, Mori M, Arai K etal. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 2010; 16:1443-1452.
12. McInnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004; 4:392-397.
13. Rückert R, Brandt K, Bulanova E, Mirghomizadeh F, Paus R, Bulfone-Paus S. Dendritic cell-derived IL-15 controls the induction of CD8 T cell immune responses. Eur J Immunol 2003; 33:3493-3503.
14. Villadsen LS, Schuurman J, Beurskens F etal. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003; 112:1571-1580.
15. Shandley S, Martinez S, Krolick K. IL-4 receptor as a bridge between the immune system and muscle in experimental myasthenia gravis I: up-regulation of muscle IL-15 by IL-4. Clin Immunol 2009; 132:246-256.
16. Stegall T, Krolick KA. Myocytes respond to both interleukin-4 and interferon-gamma: cytokine responsiveness with the potential to influence the severity and course of experimental myasthenia gravis. Clin Immunol 2000; 94:133-139.
17. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999; 17:701-738.
18. Ostlie N, Milani M, Wang W, Okita D, Conti-Fine BM. Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice. J Immunol 2003; 170:604-612.
19. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114:853-865.
20. Berrih-Aknin S, Ruhlmann N, Bismuth J etal. CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia. Ann Neurol 2009; 66:521-531.
21. Nabarra B, Pontoux C, Godard C, Osborne-Pellegrin M, Ezine S. Neoplastic transformation and angiogenesis in the thymus of transgenic mice expressing SV40 T and t antigen under an L-pyruvate kinase promoter (SV12 mice). Int J Exp Pathol 2005; 86:397-413.